Eventos adversos associados ao dupilumabe no tratamento de doenças inflamatórias crônicas tipo 2

Aldo José Fernandes Costa; Marcelo Vivolo Aun; Sergio Duarte Dortas-Junior; Fabrício Prado Monteiro; Filipe Wanick Sarinho; Marta de Fátima Rodrigues da Cunha Guidacci; Martti Anton Antila; João Negreiros Tebyriça; Nelson Augusto Rosario-Filho; Norma de Paula M. Rubini

doi:10.4322/2526-5393.20250040

Artigo de Revisão

Eventos adversos associados ao dupilumabe no tratamento de doenças inflamatórias crônicas tipo 2

Adverse events associated with dupilumab in the treatment of chronic type 2 inflammatory diseases

Aldo José Fernandes Costa, Marcelo Vivolo Aun, Sergio Duarte Dortas-Junior, Fabrício Prado Monteiro, Filipe Wanick Sarinho, Marta de Fátima Rodrigues da Cunha Guidacci, Martti Anton Antila, João Negreiros Tebyriça, Nelson Augusto Rosario-Filho, Norma de Paula M. Rubini

http://dx.doi.org/10.4322/2526-5393.20250040 Arq Asma Alerg Imunol, vol.9, n4, p.400-407, 2025

PDF

Downloads: 1

Resumo

Os imunobiológicos revolucionaram o manejo das doenças inflamatórias crônicas do tipo 2 (T2). Até setembro de 2025, estão aprovados no Brasil o uso do omalizumabe, mepolizumabe, benralizumabe, dupilumabe, tezepelumabe e lebrikizumabe para tratamento de uma ou mais dessas condições alérgicas que envolvem a inflamação T2. Embora muito seguros, eventos adversos associados ao uso dessas terapias podem ocorrer. Os membros do Departamento Científico de Imunobiológicos da Associação Brasileira de Alergia e Imunologia (ASBAI) no biênio 2025-2026 consideraram compilar dados da literatura científica acerca desses eventos adversos, e ao longo dos próximos números escreverão artigos sobre esse tópico. Nessa primeira revisão, apresentamos e discutimos os possíveis eventos adversos associados ao uso do dupilumabe.

Palavras-chave

Anticorpos monoclonais, produtos biológicos, efeitos colaterais e reações adversas a medicamentos, segurança.

Abstract

Biologic agents have revolutionized the management of chronic type 2 (T2) inflammatory diseases. As of September 2025, omalizumab, mepolizumab, benralizumab, dupilumab, tezepelumab, and lebrikizumab had been approved in Brazil for the treatment of one or more allergic conditions associated with T2 inflammation. Although these therapies are generally very safe, adverse events may occur. The members of the Scientific Department of Biologic Agents of the Brazilian Association of Allergy and Immunology (ASBAI) for the 2025–2026 term proposed compiling data from the scientific literature regarding these adverse events and, over the coming issues of this journal, will publish articles on this topic. In this first review, we present and discuss the potential adverse events associated with dupilumab therapy.

Keywords

Dupilumab, monoclonal antibodies, biologic agents, adverse drug reactions, safety, type 2 inflammation.

Referências

1. Sarinho FW, Rubini NPM, Costa AJF, Silva ECF, Monteiro FP, Serpa FS, et al. Practical guide for the use of immunobiologics in allergic diseases – ASBAI. Arq Asma Alerg Imunol. 2023;7(4):339-66. doi:10.5935/2526-5393.20230054-en.

2. Bavbek S, Pagani M, Alvarez-Cuesta E, Castells M, Dursun AB, Hamadi S, et al. Hypersensitivity reactions to biologicals: an EAACI position paper. Allergy. 2022;77(1):39-54. doi:10.1111/all.14984.

3. Demoly P, Adkinson NF, Brockow K, Castells M, Chiriac AM, Greenberger PA, et al. International consensus on drug allergy. Allergy. 2014;69(4):420-37.

4. Beck LA, Thaçi D, Hamilton JD, Graham NM, Bieber T, Rocklin R, et al. Dupilumab treatment in adults with moderate-to-severe atopic dermatitis. N Engl J Med. 2014;371(2):130-9. doi:10.1056/NEJMoa1314768.

5. Thaçi D, Simpson EL, Beck LA, Bieber T, Blauvelt A, Papp K, et al. Efficacy and safety of dupilumab in adults with moderate-to-severe atopic dermatitis inadequately controlled by topical treatments: a randomized, placebo-controlled, dose-ranging phase 2b trial. Lancet. 2016;387(10013):40-52. doi:10.1016/S0140-6736(15)00462-9.

6. Simpson EL, Bieber T, Guttman-Yassky E, Beck LA, Blauvelt A, Cork MJ, et al. Two phase 3 trials of dupilumab versus placebo in atopic dermatitis. N Engl J Med. 2016;375(24):2335-48. doi:10.1056/NEJMoa1610020.

7. Bachert C, Han JK, Desrosiers M, Hellings PW, Amin N, Lee SE, et al. Efficacy and safety of dupilumab in patients with severe chronic rhinosinusitis with nasal polyps (LIBERTY NP SINUS-24 and LIBERTY NP SINUS-52). Lancet. 2019;394(10209):1638-50. doi:10.1016/S0140-6736(19)31899-8.

8. Busse WW, Maspero JF, Rabe KF, Papi A, Wenzel SE, Ford LB, et al. Liberty Asthma QUEST: phase 3 randomized, double-blind, placebo-controlled study to evaluate dupilumab efficacy and safety in patients with uncontrolled moderate-to-severe asthma. Adv Ther. 2018;35(5):737-48. doi:10.1007/s12325-018-0701-0.

9. Boscia G, Spataro F, Desantis V, Solimando AG, Vacca A, Ria R, Savastano A. Ocular side effects of dupilumab: a comprehensive overview of the literature. J Clin Med. 2025;14(7):2487. doi:10.3390/jcm14072487.

10. Yap AXY, Tan D, Koh MJ, Yang LY, Zhe KY, Wee LW. Dupilumabassociated ocular surface disease in pediatric atopic dermatitis: a single-center Asian experience. Pediatr Dermatol. 2025;42(3):481-6. doi:10.1111/pde.70050.

11. Franklin JM, Marcus AF, Sultan I, Howell A, Sinnott SJ, Green J, et al. Incidence of conjunctivitis and keratitis among individuals with moderate-to-severe atopic dermatitis treated with dupilumab in the United States. Dermatol Ther (Heidelb). 2025;15(4):889-901. doi:10.1007/s13555-025-01367-5.

12. Li X, Sun YQ, Liu MM, Tang JF. Real-world pharmacovigilance analysis of drug-related conjunctivitis using the FDA adverse event reporting system database. Sci Rep. 2025;15(1):13407. doi:10.1038/s41598-025-92796-x.

13. Achten R, Thijs J, van der Wal M, van Luijk C, de Graaf M, Bakker D, et al. Dupilumab-associated ocular surface disease in atopic dermatitis patients. Allergy. 2023;78(8):2266-76. doi:10.1111/all.15717.

14. Castro M, Corren J, Pavord ID, Maspero J, Wenzel S, Rabe KF, et al. Dupilumab efficacy and safety in moderate-to-severe uncontrolled asthma. N Engl J Med. 2018;378(26):2486-96. doi:10.1056/NEJMoa1804092.

15. Chauvin A, Belhadi D, Dupin C, Guilleminault L, Boudjemaa A, Ghourabi N, et al. Long-term effectiveness and safety of dupilumab in severe asthma: a 5-year real-world multicenter study. J Allergy Clin Immunol Pract. 2025;S2213-98(25)00527-6. doi:10.1016/j.jaip.2025.05.050.

16. Caminati M, Maule M, Bagnasco D, Beghè B, Braido F, Brussino L, et al. Profiling blood hypereosinophilia in patients on dupilumab treatment for respiratory conditions. J Allergy Clin Immunol Pract. 2025;13(6):1367-74. doi:10.1016/j.jaip.2025.01.014.

17. Strong A, Lin T, Sverrild A, Mackay A, Lee J, Zubrinich C, et al. Dupilumab-associated hypereosinophilia in severe asthma. ERJ Open Res. 2024;10(4):00048-2024. doi:10.1183/23120541.00048-2024.

18. Jo CE, Finstad A, Georgakopoulos JR, Piguet V, Yeung J, Drucker AM. Facial and neck erythema associated with dupilumab treatment: a systematic review. J Am Acad Dermatol. 2021;84(5):1339-47. doi:10.1016/j.jaad.2020.10.067.

19. Larney C, Foley P, Wu J, Daniel BS. Real world side-effects of dupilumab: a narrative review. Australas J Dermatol. 2025. doi:10.1111/ajd.14557.

20. Napolitano M, Scalvenzi M, Fabbrocini G, Cinelli E, Patruno C. Occurrence of psoriasiform eruption during dupilumab therapy for adult atopic dermatitis: a case series. Dermatol Ther. 2019;32(6):e13142. doi:10.1111/dth.13142.

21. Maronese CA, Valenti M, Moltrasio C, Romagnuolo M, Ferrucci SM, Gilliet M, et al. Paradoxical psoriasis: an updated review. J Invest Dermatol. 2024;144(11):2364-76. doi:10.1016/j.jid.2024.05.011.

22. Eichenfield LF, Bieber T, Beck LA, Simpson EL, Thaçi D, de Bruin-Weller M, et al. Infections in dupilumab clinical trials in atopic dermatitis. Am J Clin Dermatol. 2019;20(3):443-456. doi:10.1007/s40257-019-00447-3.

23. Simpson EL, Schlievert PM, Yoshida T, Lussier S, Boguniewicz M, Hata T, et al. Rapid reduction in Staphylococcus aureus in atopic dermatitis subjects following dupilumab treatment. J Allergy Clin Immunol. 2023;152(5):1179-95. doi:10.1016/j.jaci.2023.05.026.

24. Napolitano M, Ruggiero A, Patruno C. Dupilumab-associated inflammatory arthritis: a literature review. Clin Exp Dermatol. 2024;49(4):307-12. doi:10.1111/ced.15371.

25. Woodbury MJ, Smith JS, Merola JF. Dupilumab-associated arthritis: a dermatology–rheumatology perspective. Am J Clin Dermatol. 2023;24(6):859-64. doi:10.1007/s40257-023-00768-5.

26. Dorling M, Hernaiz-Leonardo JC, Pascual A, Janjua A, Thamboo A, Javer A. Real-world adverse events after type 2 biologic use in chronic rhinosinusitis with nasal polyps. Laryngoscope. 2024;134(7):3054-9. doi:10.1002/lary.30718.

27. Schneeweiss MC, Wyss R, Schneeweiss S, Anand P, Jin Y, Dicesare E, et al. Joint pain in patients with atopic dermatitis receiving dupilumab. J Am Acad Dermatol. 2024;90(1):134-7. doi:10.1016/j.jaad.2023.08.047.

28. Annadata VS, Huynh PP, Liang J. Arthritis-related adverse reactions of dupilumab in treatment of chronic rhinosinusitis. Laryngoscope. 2025 Dec;135(12):4571-7. doi: 10.1002/lary.32439.

29. Jay R, Rodger J, Zirwas M. Review of dupilumab-associated inflammatory arthritis: an approach to clinical analysis and management. JAAD Case Rep. 2022;21:14-8. doi:10.1016/j.jdcr.2022.06.022.

30. Cabrera-Perez JS, Carey VJ, Odejide OO, Singh S, Kupper TS, Pillai SS, et al. Integrative epidemiology and immunotranscriptomics uncover a risk and potential mechanism for cutaneous lymphoma with dupilumab therapy. J Allergy Clin Immunol. 2025;155(5):1584-94. doi:10.1016/j.jaci.2024.11.027.

31. Hasan I, Parsons L, Duran S, Zinn Z. Dupilumab therapy for atopic dermatitis and risk of cutaneous T-cell lymphoma. J Am Acad Dermatol. 2024;91(2):255-8. doi:10.1016/j.jaad.2024.02.008.

32. Ma SK, Brumbaugh B, Saff RR, Phipatanakul W, Tsai YC, et al. Dupilumab and lymphoma risk among patients with asthma. Eur Respir J. 2025;2500139. doi:10.1183/13993003.00139-2025.

33. Avallone G, Cavallo F, Tancredi A, Maronese CA, Bertello M, Fraghì A, et al. Association between maternal dupilumab exposure and pregnancy outcomes. J Eur Acad Dermatol Venereol. 2024;38(9):1799-1808. doi:10.1111/jdv.19012.

34. Palumbo CM, Aun MV. Type 2 inflammatory diseases: safety profile of biologics and small molecules during pregnancy. Arq Asma Alerg Imunol. 2024;8(4):377-90. doi: 10.5935/2526-5393.20240051-en.

35. Regeneron Pharmaceuticals Inc. Dupixent (dupilumab) package insert. Tarrytown (NY): Regeneron Pharmaceuticals; 2023.

36. Siegfried EC, Lee LW, Spergel JM, et al. A case series of live attenuated vaccine administration in dupilumab-treated children with atopic dermatitis. Br J Dermatol. 2023;188(Suppl 2):ljac140.036. doi:10.1093/bjd/ljac140.036.

37. Martinez-Cabriales AS, Kirchhof MG, Constantinescu CM, Murguia-Favela L, Ramien ML. Recommendations for vaccination in children with atopic dermatitis treated with dupilumab. Am J Clin Dermatol. 2021;22(4):443-55. doi:10.1007/s40257-021-00607-6.

38. Bruess GES, Barry KK, Olsen GM, Foschi CM, Cook E, Liegl M, et al. Evaluating Outcomes of Live-Attenuated Vaccine Administration in Pediatric Patients on Dupilumab for Atopic Dermatitis. Pediatr Dermatol. 2026 Mar-Apr;43(2):330-2. doi: 10.1111/pde.70033.

39. Lieberman JA, Chu DK, Ahmed T, Dribin TE, Abrams EM, Anagnostou A, et al. A systematic review and expert Delphi Consensus recommendation on the use of vaccines in patients receiving dupilumab: A position paper of the American College of Allergy, Asthma and Immunology. Ann Allergy Asthma Immunol. 2024 Sep;133(3):286-94. doi: 10.1016/j.anai.2024.05.014.

Submetido em:
13/09/2025

Aceito em:
29/01/2026